Pfizer and BioNTech paused a government-ordered U.S. post-marketing COVID-19 vaccine study after slow enrollment prevented the companies from generating relevant post-marketing data in healthy adults aged 50 to 64. The trial aimed to enroll roughly 25,000–30,000 participants but recruitment stopped following epidemiological reviews and ongoing difficulty meeting health criteria. The companies said the pause is due to recruitment and data-collection limitations rather than safety or benefit-risk concerns, tied to FDA requirements that include placebo control arms for specific decision-making. The development highlights the operational fragility of large vaccine commitments in a shifting public interest environment and may further complicate evidence generation under evolving regulatory expectations.